ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org188, 07 Jul 2025 08:07:62 +00:00188, 07 Jul 2025 08:07:62 +00:00Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC https://www.esmo.orgnull<p>Findings from the KEYNOTE-689 study</p>noreply@esmo.org2d7428ab-7276-4d5d-8d1a-3e54441ee026Mon, 07 Jul 2025 07:07:00 +00:00ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs https://www.esmo.orgnull<p>A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care</p>noreply@esmo.orgae58f0e6-d30c-40b1-8b9d-44bb4b95b975Fri, 04 Jul 2025 08:07:00 +00:00ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe https://www.esmo.orgnull<p>ESMO welcomes the publication of the European Commission’s Life Sciences Strategy, and in particular its commitment to “propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics” by the end of 2025</p>noreply@esmo.org2aa7e346-e9f3-464f-8b7f-eedc2cf0bcc8Fri, 04 Jul 2025 08:07:00 +00:00FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies</p>noreply@esmo.orgf215244a-a78a-4a69-908e-4905f8486707Fri, 04 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Marketing Authorisation for Nirogacestat https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with progressing desmoid tumours</p>noreply@esmo.orgfe749dc9-324d-4372-b5ae-b1cf5b76958cThu, 03 Jul 2025 07:07:00 +00:00Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma https://www.esmo.orgnull<p>Findings from the DESTINY-Gastric04 study</p>noreply@esmo.org6d550034-87de-45f0-804e-d114de9c386bWed, 02 Jul 2025 07:07:00 +00:00ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation https://www.esmo.orgnull<p>Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework</p>noreply@esmo.orgdc899918-e0a1-46e0-9177-bdee6261b89cTue, 01 Jul 2025 08:07:00 +00:00Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 https://www.esmo.orgnull<p>Findings from the KOMET study</p>noreply@esmo.org8669b726-80a8-4df1-9ae4-ee4c40e0176eTue, 01 Jul 2025 07:07:00 +00:00Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer https://www.esmo.orgnull<p>Findings from the INAVO120 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org188, 07 Jul 2025 08:07:21 +00:00188, 07 Jul 2025 08:07:21 +00:00Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC https://www.esmo.orgnull<p>Findings from the KEYNOTE-689 study</p>noreply@esmo.org2d7428ab-7276-4d5d-8d1a-3e54441ee026Mon, 07 Jul 2025 07:07:00 +00:00ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs https://www.esmo.orgnull<p>A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care</p>noreply@esmo.orgae58f0e6-d30c-40b1-8b9d-44bb4b95b975Fri, 04 Jul 2025 08:07:00 +00:00ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe https://www.esmo.orgnull<p>ESMO welcomes the publication of the European Commission’s Life Sciences Strategy, and in particular its commitment to “propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics” by the end of 2025</p>noreply@esmo.org2aa7e346-e9f3-464f-8b7f-eedc2cf0bcc8Fri, 04 Jul 2025 08:07:00 +00:00FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies</p>noreply@esmo.orgf215244a-a78a-4a69-908e-4905f8486707Fri, 04 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Marketing Authorisation for Nirogacestat https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with progressing desmoid tumours</p>noreply@esmo.orgfe749dc9-324d-4372-b5ae-b1cf5b76958cThu, 03 Jul 2025 07:07:00 +00:00Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma https://www.esmo.orgnull<p>Findings from the DESTINY-Gastric04 study</p>noreply@esmo.org6d550034-87de-45f0-804e-d114de9c386bWed, 02 Jul 2025 07:07:00 +00:00ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation https://www.esmo.orgnull<p>Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework</p>noreply@esmo.orgdc899918-e0a1-46e0-9177-bdee6261b89cTue, 01 Jul 2025 08:07:00 +00:00Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 https://www.esmo.orgnull<p>Findings from the KOMET study</p>noreply@esmo.org8669b726-80a8-4df1-9ae4-ee4c40e0176eTue, 01 Jul 2025 07:07:00 +00:00Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer https://www.esmo.orgnull<p>Findings from the INAVO120 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org188, 07 Jul 2025 08:07:73 +00:00188, 07 Jul 2025 08:07:73 +00:00Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC https://www.esmo.orgnull<p>Findings from the KEYNOTE-689 study</p>noreply@esmo.org2d7428ab-7276-4d5d-8d1a-3e54441ee026Mon, 07 Jul 2025 07:07:00 +00:00ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs https://www.esmo.orgnull<p>A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care</p>noreply@esmo.orgae58f0e6-d30c-40b1-8b9d-44bb4b95b975Fri, 04 Jul 2025 08:07:00 +00:00ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe https://www.esmo.orgnull<p>ESMO welcomes the publication of the European Commission’s Life Sciences Strategy, and in particular its commitment to “propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics” by the end of 2025</p>noreply@esmo.org2aa7e346-e9f3-464f-8b7f-eedc2cf0bcc8Fri, 04 Jul 2025 08:07:00 +00:00FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies</p>noreply@esmo.orgf215244a-a78a-4a69-908e-4905f8486707Fri, 04 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Marketing Authorisation for Nirogacestat https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with progressing desmoid tumours</p>noreply@esmo.orgfe749dc9-324d-4372-b5ae-b1cf5b76958cThu, 03 Jul 2025 07:07:00 +00:00Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma https://www.esmo.orgnull<p>Findings from the DESTINY-Gastric04 study</p>noreply@esmo.org6d550034-87de-45f0-804e-d114de9c386bWed, 02 Jul 2025 07:07:00 +00:00ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation https://www.esmo.orgnull<p>Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework</p>noreply@esmo.orgdc899918-e0a1-46e0-9177-bdee6261b89cTue, 01 Jul 2025 08:07:00 +00:00Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 https://www.esmo.orgnull<p>Findings from the KOMET study</p>noreply@esmo.org8669b726-80a8-4df1-9ae4-ee4c40e0176eTue, 01 Jul 2025 07:07:00 +00:00Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer https://www.esmo.orgnull<p>Findings from the INAVO120 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org188, 07 Jul 2025 08:07:45 +00:00188, 07 Jul 2025 08:07:45 +00:00Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC https://www.esmo.orgnull<p>Findings from the KEYNOTE-689 study</p>noreply@esmo.org2d7428ab-7276-4d5d-8d1a-3e54441ee026Mon, 07 Jul 2025 07:07:00 +00:00ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs https://www.esmo.orgnull<p>A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care</p>noreply@esmo.orgae58f0e6-d30c-40b1-8b9d-44bb4b95b975Fri, 04 Jul 2025 08:07:00 +00:00ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe https://www.esmo.orgnull<p>ESMO welcomes the publication of the European Commission’s Life Sciences Strategy, and in particular its commitment to “propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics” by the end of 2025</p>noreply@esmo.org2aa7e346-e9f3-464f-8b7f-eedc2cf0bcc8Fri, 04 Jul 2025 08:07:00 +00:00FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies</p>noreply@esmo.orgf215244a-a78a-4a69-908e-4905f8486707Fri, 04 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Marketing Authorisation for Nirogacestat https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with progressing desmoid tumours</p>noreply@esmo.orgfe749dc9-324d-4372-b5ae-b1cf5b76958cThu, 03 Jul 2025 07:07:00 +00:00Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma https://www.esmo.orgnull<p>Findings from the DESTINY-Gastric04 study</p>noreply@esmo.org6d550034-87de-45f0-804e-d114de9c386bWed, 02 Jul 2025 07:07:00 +00:00ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation https://www.esmo.orgnull<p>Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework</p>noreply@esmo.orgdc899918-e0a1-46e0-9177-bdee6261b89cTue, 01 Jul 2025 08:07:00 +00:00Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 https://www.esmo.orgnull<p>Findings from the KOMET study</p>noreply@esmo.org8669b726-80a8-4df1-9ae4-ee4c40e0176eTue, 01 Jul 2025 07:07:00 +00:00Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer https://www.esmo.orgnull<p>Findings from the INAVO120 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org188, 07 Jul 2025 08:07:55 +00:00188, 07 Jul 2025 08:07:55 +00:00Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC https://www.esmo.orgnull<p>Findings from the KEYNOTE-689 study</p>noreply@esmo.org2d7428ab-7276-4d5d-8d1a-3e54441ee026Mon, 07 Jul 2025 07:07:00 +00:00ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs https://www.esmo.orgnull<p>A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care</p>noreply@esmo.orgae58f0e6-d30c-40b1-8b9d-44bb4b95b975Fri, 04 Jul 2025 08:07:00 +00:00ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe https://www.esmo.orgnull<p>ESMO welcomes the publication of the European Commission’s Life Sciences Strategy, and in particular its commitment to “propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics” by the end of 2025</p>noreply@esmo.org2aa7e346-e9f3-464f-8b7f-eedc2cf0bcc8Fri, 04 Jul 2025 08:07:00 +00:00FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies</p>noreply@esmo.orgf215244a-a78a-4a69-908e-4905f8486707Fri, 04 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Marketing Authorisation for Nirogacestat https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with progressing desmoid tumours</p>noreply@esmo.orgfe749dc9-324d-4372-b5ae-b1cf5b76958cThu, 03 Jul 2025 07:07:00 +00:00Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma https://www.esmo.orgnull<p>Findings from the DESTINY-Gastric04 study</p>noreply@esmo.org6d550034-87de-45f0-804e-d114de9c386bWed, 02 Jul 2025 07:07:00 +00:00ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation https://www.esmo.orgnull<p>Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework</p>noreply@esmo.orgdc899918-e0a1-46e0-9177-bdee6261b89cTue, 01 Jul 2025 08:07:00 +00:00Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 https://www.esmo.orgnull<p>Findings from the KOMET study</p>noreply@esmo.org8669b726-80a8-4df1-9ae4-ee4c40e0176eTue, 01 Jul 2025 07:07:00 +00:00Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer https://www.esmo.orgnull<p>Findings from the INAVO120 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00ESMO Newshttps://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.org188, 07 Jul 2025 08:07:77 +00:00188, 07 Jul 2025 08:07:77 +00:00Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC https://www.esmo.orgnull<p>Findings from the KEYNOTE-689 study</p>noreply@esmo.org2d7428ab-7276-4d5d-8d1a-3e54441ee026Mon, 07 Jul 2025 07:07:00 +00:00ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO Europe Report Ahead of 2025 UN High-Level Meeting on NCDs https://www.esmo.orgnull<p>A new WHO Europe report on regional stakeholder priorities concerning noncommunicable diseases (NCDs) and mental health aligns with ESMO recommendations on cancer prevention and care</p>noreply@esmo.orgae58f0e6-d30c-40b1-8b9d-44bb4b95b975Fri, 04 Jul 2025 08:07:00 +00:00ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step Towards a Stronger, Healthier Europe https://www.esmo.orgnull<p>ESMO welcomes the publication of the European Commission’s Life Sciences Strategy, and in particular its commitment to “propose legislation that strikes a balance between simplifying EU regulations related to medical devices and in vitro diagnostics” by the end of 2025</p>noreply@esmo.org2aa7e346-e9f3-464f-8b7f-eedc2cf0bcc8Fri, 04 Jul 2025 08:07:00 +00:00FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies</p>noreply@esmo.orgf215244a-a78a-4a69-908e-4905f8486707Fri, 04 Jul 2025 07:07:00 +00:00EMA Recommends Granting a Marketing Authorisation for Nirogacestat https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with progressing desmoid tumours</p>noreply@esmo.orgfe749dc9-324d-4372-b5ae-b1cf5b76958cThu, 03 Jul 2025 07:07:00 +00:00Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma https://www.esmo.orgnull<p>Findings from the DESTINY-Gastric04 study</p>noreply@esmo.org6d550034-87de-45f0-804e-d114de9c386bWed, 02 Jul 2025 07:07:00 +00:00ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of Medical and In Vitro Diagnostic Devices in the New EU Public Consultation https://www.esmo.orgnull<p>Clear clinical standards and structured expertise must anchor the EU’s approach to cancer diagnostics under the Health Technology Assessment (HTA) framework</p>noreply@esmo.orgdc899918-e0a1-46e0-9177-bdee6261b89cTue, 01 Jul 2025 08:07:00 +00:00Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 https://www.esmo.orgnull<p>Findings from the KOMET study</p>noreply@esmo.org8669b726-80a8-4df1-9ae4-ee4c40e0176eTue, 01 Jul 2025 07:07:00 +00:00Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer https://www.esmo.orgnull<p>Findings from the INAVO120 study</p>noreply@esmo.orgb951eb62-bb97-4923-8181-562391b74606Mon, 30 Jun 2025 07:06:00 +00:00FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the ARANOTE study</p>noreply@esmo.org71cae980-92df-4341-aad8-72119afb49c6Fri, 27 Jun 2025 07:06:00 +00:00EMA Recommends Granting a Marketing Authorisation for Inavolisib https://www.esmo.orgnull<p>It is intended for the treatment of adult patients with <em>PIK3CA</em>-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer</p>noreply@esmo.org26ed0eb1-6cad-4120-ac54-484b3575cd0fThu, 26 Jun 2025 07:06:00 +00:00Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC https://www.esmo.orgnull<p>Findings from the BREAKWATER study</p>noreply@esmo.orgc7233b12-26fd-4902-adbe-b539a861667aWed, 25 Jun 2025 07:06:00 +00:00ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July https://www.esmo.orgnull<p>The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies</p>noreply@esmo.orgfdf17ac1-7308-4062-a6e7-d388d21a4389Wed, 25 Jun 2025 06:06:00 +00:00Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone https://www.esmo.orgnull<p>Findings from the CheckMate 816 study</p>noreply@esmo.org2441830b-ee0f-4bce-b4d7-5f239d388b1dTue, 24 Jun 2025 07:06:00 +00:00ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer https://www.esmo.orgnull<p>In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)</p>noreply@esmo.org2411b658-ffcd-4d83-987d-ac93788fca92Mon, 23 Jun 2025 13:06:00 +00:00Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer https://www.esmo.orgnull<p>Findings from the ROSELLA study</p>noreply@esmo.org75324d67-5154-4f59-ae40-7cc3916e23bdMon, 23 Jun 2025 07:06:00 +00:00FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal https://www.esmo.orgnull<p>Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies</p>noreply@esmo.org7cc3533d-efcb-414b-beab-f974542cec23Fri, 20 Jun 2025 08:06:00 +00:00EMA Recommends Extension of Therapeutic Indications for Acalabrutinib https://www.esmo.orgnull<p>A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax</p>noreply@esmo.orgb6a9b38b-32b5-44d2-82e1-27de189d137aWed, 18 Jun 2025 08:06:00 +00:00Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma https://www.esmo.orgnull<p>Findings from the C-POST study</p>noreply@esmo.orga082d1b4-6664-4eb6-9a9f-58df174a0c43Wed, 18 Jun 2025 08:06:00 +00:00French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research https://www.esmo.orgnull<p>Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research</p>noreply@esmo.orga9ca2d68-adcf-4143-b95a-35d1f35dedb3Tue, 17 Jun 2025 09:06:00 +00:00